OBJECTIVE:
To determine whether there is association between skin tattoos, Hepatits-B and prisons, to investigate risk behaviors for Hepatitis-B and to describe characteristics of person who have tattoos. METHODS: This retrospective study consisted of a self-administered survey, and an ELISA blood test for viral hepatitis B. The study sample consisted of all 1/2000 privates at Adisorn Fort Hospital Saraburi who had tattoos (n1 = 46) and simple random sampling of another group of 46 volunteer privates who did not have tattoos. RESULTS: All privates (N = 92) were male, age 22.88 b 1.41 years, 67 (72.8%) had graduated from elementary and high school, 29 were positive for Hepatitis-B antibodies (31.5%), 41 (44.6%) had sex with prostitutes, 3 (3.3%) did not use condom, 4 (4.3%) shared razors, 1 (1.1%) shared needles, 25 (27.2%) had been in jail, 87 (94.6%) drank alcohol, 43 (46.7%) had used amphetamines. Twenty (28.6%) had tattoos on 2 arms. Ten (14.3%) had tattoos on their back, 9 (19.6%) obtained their tattoos while in prison, 15 (32.6%) had a tattoo that was greater than 20% of the body's surface area. There was an association between skin tattoos and Hepatitis B (Chi Square, p < .01, OR: 15.9, 95% CI: 2.1-18.8), There was no association between having been in jail and Hepatitis-B. Logistic regression was employed to find factors for Hepatitis-B. The variables that were associated with Hepatitis-B (<0.05) were entered procedure to identify association with Hepatitis-B. Hit rate was 87.9, Pseudo R Square 0.464, Skin tattoos, a history of a family member with Hepatitis-B, and sharing needles increased the chance of getting Hepatitis-B. CONCLUSIONS: There were associations between jails and tattoos and viral hepatitis-B. Hygiene in tattoo' shops should be controlled by the government.
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CONSUMPTION OF ANTIBIOTICS IN EUROPE: RESULTS OF THE ESAC RETROSPECTIVE DATA COLLECTION
Ferech M, Elseviers M,Vander Stichele R, Goossens H ESAC Management Team, University of Antwerp, Antwerp, Belgium OBJECTIVES: ESAC (European Surveillance of Antibiotic Consumption, granted by DG SANCO of the EC) is an international network of national surveillance systems, aiming to collect comparable antibiotic consumption data in Europe. During the first phase, data accessibility and validity, as well as strengths and weaknesses of national systems were assessed. METHODS: Quarterly data were to be collected retrospectively (1997) (1998) (1999) (2000) (2001) from ambulatory (AC) and hospital care (HC) in 31 countries, using ATC/DDD classification (WHO, version 2001) , and expressing results in DDD/1000 inhabitants per day (DID). RESULTS: AC use data were provided by 25 countries; 21 were suitable for international comparison. The remaining 3 were not comprehensive or not in a format enabling international comparison (TU). Quarterly AC data were delivered by 10 countries. HC use data were provided by 23 countries; 21 were suitable for international comparison, 14 of them were based on a limited sample. In 2001, AC use in Europe varied between 10.0 DID (NL) and 32.9 DID (FR). Other high consumers were (in decreasing order) GR, IT, LU, PL, PT, BE and SK, all with a total use exceeding 24 DID. During the observation period of 5 years, consumption clearly increased in GR and PL and decreased in BE and ES. High seasonal fluctuations in AC were observed in BE, GR, PL and SI. Large regional differences could be observed in consumption patterns. Northern European countries (NO, SE, FI, DK, NL) are low consumers using commonly narrow spectrum penicillins while Southern European countries are high consumers using broad spectrum penicillins and exceptionally high proportions of cephalosporins, macrolides and quinolones. CONCLU-SIONS: An intriguingly high variation in antibiotic use in Europe was observed and needs to be related to social, cultural and economic determinants of use as well as to variation in resistance patterns. Especially in AC, countries seem to cluster in regional consumption patterns.
